News

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...
While FDA Commissioner Marty Makary emphasizes learning and humility, the FDA has systematically removed the very experience ...
The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and ...
FDA Commissioner Marty Makary, M.D., has made his pick for the next director of the FDA’s Center for Drug Evaluation and ...
The FDA will select at most five companies that align with national priorities, including lower drug prices and increased ...
Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the ...
The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...
Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is getting better, and use is not mandatory.
Despite recent staffing reductions and leadership transitions at the FDA, pharmaceutical and medical device manufacturers should not interpret these changes as a signal of reduced regulatory ...
In a major policy change, the Food and Drug Administration has announced a plan to limit access to future COVID-19 shots only to people over 65 years old or those with an underlying health ...
Renee Gala named next CEO of Jazz Pharmaceuticals: Gala will take over as president and CEO on August 11, 2025, following Bruce Cozadd’s planned retirement. · Gala credited with nearly doubling Jazz’s ...